VEGFA and wet macular degeneration: (2018) describe preclinical evidence of long-term expression and efficacy of a single intravitreal injection of ADVM-022, a gene-therapy vector encoding aflibercept, an approved anti-VEGFA therapy for wet age-related macular degeneration (wAMD), and which has the potential to alleviate frequent ocular injections required to treat wAMD.